Published Date: 02 Mar 2023
The latest studies of long-acting ART show benefits even in people who are not immune. Meanwhile, early proof-of-concept results for twice-yearly injection are encouraging.
Read Full NewsNew findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.
A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.
FDA Approves First Dual-Agent Eye Drop for Near Vision Loss
1.
More pain, more gain? New biopsy technique found to improve prostate cancer detection
2.
AI-based liquid biopsy shows promise for detecting brain cancer
3.
Researchers Challenge USPSTF's Lung Cancer Screening Criteria
4.
When Should Immunocompromised Individuals Receive a COVID Booster?
5.
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
1.
Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications
2.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
3.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
4.
CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights
5.
Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation